
Opinion|Videos|January 29, 2026
Reflecting on Trial Limitations in GCA: Painting a Future for IL-17A Targeting Therapies
Advertisement
Episodes in this series

This video covers the following questions:
- Do these phase 3 results reflect the limitations of IL‑17A as a therapeutic target in GCA, or might issues in trial design, patient selection, or taper regimen explain the discrepancy between Phase II and Phase III outcomes? What role do you see for secukinumab in future GCA treatment?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
New Antifibrotics Are Changing the Treatment Calculus in ILD
2
When Blisters Don't Look Like Blisters: Diagnosing Pemphigus, Pemphigoid
3
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
4
Evaluating Clinical and Real-World Evidence in Hypercortisolism
5























































































